Potential Strategies for the Eradication of Multidrug-Resistant Gram-Negative Bacterial Infections

Frieden M. Antibiotic Resistance Threats In The United States (2013). www.his.org.uk/files/3713/7941/9908/Antibiotic_Resistance_Threats_in_the_United_States_2013.pdf.

O'Neill J. Vaccines And Alternative Approaches: Reducing Our Dependence On Antimicrobials (2016). http://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf.

10.1016/S1473-3099(13)70318-9

Cantóna R, Horcajadad JP, Oliver A, Garbajosaa PR, Vila J. Inappropriate use of antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial resistance. Enferm. Infecc. Microbiol. Clin. 31 (Suppl. 4 ), 3 – 11 (2013).

Health First Europe. EU Policy Recommendations on Increased Patient Safety and the Prevention of Healthcare Associated Infections (2015). http://www.healthfirsteurope.org/uploads/Modules/Newsroom/hfe-hcai-paper-08022012-print-quality-2.pdf.

UK 5 Year Antimicrobial Resistance (AMR) Strategy 2013– 2018 Annual Progress Report And Implementation Plan (2014). www.gov.uk/government/uploads/system/uploads/attachment_data/file/385733/UK_AMR_annual_report.pdf.

10.4137/PMC.S14459

10.1016/j.ijantimicag.2015.05.003

10.1155/2005/892058

Ventola CL. The antibiotic resistance crisis. Part 1: causes and threats. P T 40 (4 ), 277 – 283 (2015).

Ledford H. FDA under pressure to relax drug rules. Nature 492 (7427 ), 19 (2012).

Rigel NW, Silhavy TJ. Making a beta-barrel: assembly of outer membrane proteins in Gram-negative bacteria. Curr. Opin. Microbiol. 15 (2 ), 189 – 193 (2012).

10.1038/nrmicro3525

10.2174/138920312804871120

10.1038/nrmicro3480

10.1016/j.carres.2013.05.007

Blot N, Berrier C, Hugouvieux-Cotte-Pattat N, Ghazi A, Condemine G. The oligogalacturonate-specific porin KdgM of Erwinia chrysanthemi belongs to a new porin family. J. Biol. Chem. 277 (10 ), 7936 – 7944 (2002).

10.1016/j.bbapap.2008.11.005

Band VI, Weiss DS. Mechanisms of antimicrobial peptide resistance in Gram-negative bacteria. Antibiotics 4 (1 ), 18 – 41 (2015).

10.1128/AAC.00865-13

10.1371/journal.ppat.1002454

Dalebroux ZD, Matamouros S, Whittington D, Bishop RE, Miller SI. PhoPQ regulates acidic glycerophospholipid content of the Salmonella typhimurium outer membrane. Proc. Natl Acad. Sci. 111 (5 ), 1963 – 1968 (2014).

10.1038/nrmicro1994

Tängdén T, Adler M, Cars O, Sandegren L, Löwdin EJ. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. Antimicrob. Chemother. 68 (6 ), 1319 – 1326 (2013).

10.3389/fmicb.2015.00377

10.1016/j.bbrc.2014.05.090

10.3389/fmicb.2013.00007

10.1084/jem.70.1.1

10.3390/ph6121543

10.3390/ijms12106566

10.1007/978-1-60761-594-1_10

Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin-II: buforin-II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244 (1 ), 253 – 257 (1998).

Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. Bio. Drugs 17 (4 ), 233 – 240 (2003).

Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial mechanisms of polymyxin and bacterial resistance. Biomed. Res. Int. 679109 (2015).

10.2217/fmb.13.39

10.1016/S1473-3099(15)00424-7

10.1016/j.mib.2010.09.002

10.3390/ijms12095971

10.4062/biomolther.2012.20.1.019

10.1128/AAC.44.12.3317-3321.2000

Kondejewski LH, Jelokhani-Niaraki M, Farmer SW et al. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J. Biol. Chem. 274 (19 ), 13181 – 13192 (1999).

10.2174/092986712803251548

10.3109/03009734.2014.899279

10.1073/pnas.1409800111

10.1128/CMR.05041-11

Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin. Infect. Dis. 40 (Suppl. 2 ), S99 – S104 (2005).

10.1126/scitranslmed.3006276

Lee W, Kim KJ, Lee DG. A novel mechanism for the antibacterial effect of silver nanoparticles on Escherichia coli. Biometals 6, 1191 – 1201 (2014).

10.2147/IJN.S55015

10.4103/0976-500X.124405

Bertheta J, Damiena P, Hamzeh-Cognassea H et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clin. Immunol. 145 (3 ), 189 – 200 (2012).

Nikado H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67 (4 ), 593 – 656 (2003).

10.1016/j.mehy.2014.08.024

10.1038/srep13252

10.1007/s00018-014-1762-5

10.1042/BST0390989

10.1016/j.bpj.2008.10.044

Liu Y, Ni B, Ren JD et al. Cyclic limulus anti-lipopolysaccharide (LPS) factor-derived peptide CLP-19 antagonizes LPS function by blocking binding to LPS binding protein. Biol. Pharm. Bull. 34 (11 ), 1678 – 1683 (2011).

10.1038/nchembio.1752

10.1073/pnas.0804621105

10.1089/ars.2010.3575

10.1016/j.cell.2006.10.034

10.1111/j.1348-0421.2000.tb01244.x

10.1128/AAC.01866-13

10.3389/fmicb.2015.00660

10.1128/CMR.00117-14

Puckett SE, Reese KA, Mitev GM et al. Bacterial resistance to antisense peptide phosphorodiamidate morpholino oligomers. Antimicrob. Agents Chemother. 56 (12 ), 6147 – 6153 (2012).

Robinson R. RNAi therapeutics: how likely, how soon? PLoS Biol. 2 (1 ), e28 (2004).

10.1517/13543784.2014.930127

10.1016/S1473-3099(15)00466-1

10.1128/AAC.01695-15

10.1186/1556-276X-8-102

10.1016/j.addr.2012.09.037

10.1016/j.ejpb.2015.06.013

10.1038/nrd1632

10.1016/j.ijantimicag.2010.01.015

Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J. Drug Deliv. 837327 (2012).

10.1016/j.nantod.2014.06.003

Usui Y, Haniu H, Tsuruoka S, Saito N. Carbon nanotubes innovate on medical technology. Med. Chem. 2 (1 ), 1 – 6 (2012).

Rastogi V, Yadav P, Bhattacharya SS et al. Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J. Drug Deliv. 670815 (2014).

10.1021/la802769m

10.1021/la103110g

Liu T, Tang H, Zhao J, Li D, Li R, Sun X. A study on the bactericidal properties of Cu-coated carbon nanotubes. Front. Mater. Sci. 1 (2 ), 147 – 150 (2007).

10.3390/pathogens3040791

10.1128/AAC.44.12.3317-3321.2000

10.1039/c2cs35172b

10.1038/35086601

Rodríguez-Vázquez N, Ozores HL, Guerra A et al. Membrane-targeted self-assembling cyclic peptide nanotubes. Curr. Top. Med. Chem. 14 (23 ), 2647 – 2461 (2014).

10.1007/s12250-014-3549-0

10.4161/bact.1.2.15845

10.1128/mBio.01379-14

10.4161/viru.22683